Prilenia Therapeutics
Tel Aviv, Israel· Est.
Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.
Huntington's diseaseAmyotrophic lateral sclerosisNeurodegenerative diseasesNeurodevelopmental disorders
Technology Platform
Selective oral sigma‑1 receptor (S1R) agonism to activate neuroprotective pathways and restore cellular homeostasis in CNS disorders.
Opportunities
Successful Phase 3 data could enable rapid global approval and expansion of the S1R platform into multiple CNS disorders, creating partnership and licensing value.
Risk Factors
Reliance on a single investigational asset; clinical trial outcomes and regulatory approval remain uncertain, and competition from other neuroprotective approaches could limit market share.
Competitive Landscape
Prilenia competes with other S1R agonists and emerging gene‑therapy or antisense strategies for HD and ALS, differentiating through an oral, selective agonist with a broad neuroprotective mechanism.